최고 Media Molecule 팟캐스트 (2024)

1
Energy Policy with Your Favorite Professor starring Marco Dell’Aquila, Co-founder & Chairman of Power Capital and Inspiratia 1:03:04

1d ago1:03:04

1:03:04

The EAH team sits down with power pioneer Marco Dell’Aquila, Patient Zero of the hydrogen bug. Under his tutelage, Andrew Leedom, Patrick Molloy and Chris Jackson were motivated to launch their successful and rewarding careers in hydrogen. Alicia Eastman has also found inspiration and an excellent lunch time raconteur. About Marco Dell’Aquila: Marc…

1
Targeting Senescent Cells to Treat Aging-Related Diseases 31:44

3d ago31:44

31:44

Senescent cells, ones that no longer divide but are metabolically active, are associated with aging. They are also implicated in a broad range of aging-related diseases including cancer, diabetes, and neurodegenerative conditions. In the case of cancer, these cells can help protect tumors from a person’s immune system. Immorta Bio is seeking to add…

1
Bringing Cellular Diversity into Sharper Focus 30:35

10d ago30:35

30:35

From cell to cell within a given tissue, variability exists. Single-cell sequencing technologies from 10X Genomics is helping researchers and drug developers understand cellular diversity in tissue once thought to be made up of homogenous populations. This has the potential to lead to new understandings of diseases, open up new targets for drug dev…

1
Developing Cancer Therapies for When Damage Control Goes Awry 18:09

17d ago18:09

18:09

The DDR pathway plays a critical role in repairing DNA damage in healthy cells that would otherwise cause mutations or cell death. When this pathway is altered and becomes unable to repair this damage, mutated cells can grow out of control and become cancerous. They can also be more resistant to standard chemotherapies and radiation. Aprea Therapeu…

1
Delivering the Goods 36:06

17d ago36:06

36:06

Nearly 70 percent of patients with chronic conditions fail to take their medicines as prescribed. This can lead to poor outcomes and greater healthcare costs. Vivani Medical, which has developed implantable drug delivery technology, said it can provide steady drug release for up to six months with a single implant. This not only can address the pro…

1
Driving the Green Transformation through Innovation & Cooperation with Miguel Ángel López Borrego, CEO of thyssenkrupp AG and thyssenkrupp Decarbon Technologies 54:37

17d ago54:37

54:37

EAH spoke with Miguel, after a little over a year in the CEO post, to understand where the group is heading. He describes his plans for the Company and in particular, the DeCarbon Technologies Group, which is working with many important partners to accelerate emissions elimination innovation. About Miguel López Borrego: Miguel began his professiona…

1
Swimming in the New Oil 22:26

1M ago22:26

22:26

One of the key obstacles to developing new drugs and diagnostics is the lack of access to longitudinal biological and clinical patient data. Culmination Bio, a spin-out of Intermountain Health, is building the largest patient data platform with more than 40 years of de-identified patient electronic health records and biospecimen data. We spoke to L…

1
Does This Drug Represent “A Paradigm Shift for Small Molecule Drug Development?” 28:01

1M ago28:01

28:01

NAMPT is a critical enzyme that regulates how cells use energy. It can also play an important role in the ability of cancer cells to survive, grow, and spread. While it’s been recognized as a potential target to treat certain cancers, developing NAMPT inhibitors have been challenging because they can disrupt energy metabolism in healthy cells. Reme…

1
Exploring the Promise and Peril of CRISPR 57:36

2M ago57:36

57:36

The emergence of CRISPR, a powerful tool for gene editing, promises to correct devastating genetic diseases, but it also raises concerns about how it will be used and who will make those decisions. Neal Baer, in his new book “The Promise and Peril of CRISPR,” brings together a series of essays by bioethicists, geneticists, and others who explore et…

1
Transforming Protein Engineering with Generative AI 35:47

2M ago35:47

35:47

Speeding Protein Engineering with Whether it’s the development of new biotherapeutics, or replacing hydrocarbons from their role in industrial manufacturing, engineering proteins suited for a task is a time consuming and expensive process. Cradle Bio has developed generative AI technology to accelerate protein engineering by reducing the number of …

1
Delivering Peptide Therapies Orally 34:06

2M ago34:06

34:06

With the emergence of GLP-1 agonists to treat obesity, there has been growing interest in the use of peptide-based medicines. Protagonist Therapeutics has developed technology that can take these target specific and potent therapies and allow them to be delivered orally. The company has a collaboration with Johnson & Johnson for an oral peptide tha…

1
Creating A Drug Delivery ARMMs Race 24:42

2M ago24:42

24:42

While there have been a parade of novel therapeutic modalities in recent years, many of them are constrained by delivery challenges. Vesigen Therapeutics is developing novel drug delivery technology known as ARMMs that can transport a wide range of therapeutic payloads directly into the cytoplasm of target cells. We spoke to Paulash Mohsen, CEO of …

1
From Vision to Reality: Producing Sustainable Molecules with Gene Gebolys, World Energy Founder & CEO 55:12

2M ago55:12

55:12

The team sits down with Gene Gebolys CEO and founder of World Energy to discuss his and World Energy's journey to producing sustainable fuels and their plans in the hydrogen space. About Gene Gebolys: Gene Gebolys is the founder and CEO of World Energy. For over 25 years, World Energy has been at the forefront of commercializing renewable fuels and…

1
A Seek and Destroy Approach to Disease-Causing Proteins 37:10

2M ago37:10

37:10

The body has a natural mechanism for breaking down and clearing proteins. Arvinas is among a group of companies that’s seeking to harness this mechanism for therapeutic purposes. It has platform technology that enables the development of targeted protein degraders to breakdown disease-causing proteins. Among the benefits of this approach is that it…

1
Teaching Tolerance to Address Autoimmune Diseases 36:25

3M ago36:25

36:25

The traditional approach to treating autoimmune disease has relied on ways to suppress the immune system. COUR Pharmaceuticals is developing first-in-class therapies that instead seek to reprogram the immune system to create antigen-specific tolerance. We spoke to COUR CEO John Puisis and COUR Vice President of Research Adam Elhofy, about how the c…

1
Nuclear-enabled Hydrogen at Port of Belledune with Rishi Jain, MD of Cross River Infrastructure Partners 51:35

3M ago51:35

51:35

The team sits down with Rishi Jain to discuss Cross River’s marquee wind, hydro, nuclear, hydrogen, ammonia project in the revitalized heavy industrial Port of Belledune, New Brunswick, Canada. About Rishi Jain: Rishi is a Partner and Managing Director at Cross River Infrastructure Partners. He leads the hydrogen and nuclear business development ac…

1
A Bet That the Next Blockbuster May Already Be Inside You 22:34

3M ago22:34

22:34

The next blockbuster drug may already be in production by bacteria within your body. Bacteria produce unique chemical compounds that are bioactive and may have great therapeutic potential, but this chemical space has largely not been mined. Empress Therapeutics, a Flagship Pioneering company, is searching for such molecules by exploring the genes o…

1
A Big Mac Attack to Fight Cancer 36:37

3M ago36:37

36:37

In most cases, the immune system detects and destroys cells that could become cancerous every day. For cancer to ravage the body, it needs to evade the immune system by shutting off its response. SIRPant Immunotherapeutics is seeking to address cancer by activating and modifying a patient’s own macrophages to awaken the immune system to cancer. The…

1
Getting Animated about Bioliteracy 24:29

3M ago24:29

24:29

As the founder of SynBioBeta, John Cumbers has long evangelized to investors, entrepreneurs, and forward-thinking industrialists about the emergence of the bioeconomy. Cumbers, however, wants to share his sense of wonder about molecular biology with a broader audience through his new venture, Biological Enlightenment Studios. His ambition is for th…

1
Finding Your True Direction in Life 33:06

3M ago33:06

33:06

Hi friends, In this episode, I share what I've learned from my lifelong quest for Soul Purpose and Dharma. I also share what I've learned from the Galactic Guides—two specific vibrations that you can pay attention to navigate and ensure that you live in full alignment with your Soul. Enjoy, and let me know what you resonate with the most. Thank you…

1
Optimizing the Capital Stack with Bart White, EMEA Head of Energy Structured Finance at Santander Corporate and Investment Banking 46:53

3M ago46:53

46:53

Co-hosts Chris Jackson and Alicia Eastman had the pleasure to interview Bart White of Santander Corporate and Investment Banking (SCIB). The discussion was mostly regarding optimizing different bespoke tools to accelerate the energy transition with some case examples provided by Bart. After the interview, Patrick Molloy stepped in to unpack and dis…

1
Reshaping Clinical Trial Designs with Real-World Data 28:53

4M ago28:53

28:53

Electronic health records are a rich source of real-world data that can provide insights into health and wellness. Neal Meropol, head of research oncology at Flatiron Health, said they not only have value as a research tool for retrospective studies, but can be a treasure trove of information for prospective studies as well. We spoke to Meropol abo…

1
Using Generative AI to Produce Precise Gene Editors 23:15

4M ago23:15

23:15

Earlier this year, Profluent announced it had edited the human genome with OpenCRISPR-1, the world’s first AI-created and open-source gene editor. Though the open-source aspect helped garner attention for Profluent, it also served as a demonstration of the company’s generative AI platform to create novel CRISPR gene editors. We spoke to Hilary Eato…

1
Alfa Laval Inside with Tue Johannessen, Alfa Laval VP Strategy & Partnerships, Electrolyzer & Fuel Cell Technologies 56:43

4M ago56:43

56:43

Co-hosts Patrick Molloy, Chris Jackson, and Alicia Eastman speak with Alfa Laval’s Tue Johannessen about the company’s role in the energy transition, and more specifically about involvement in hard-to-abate sectors where hydrogen is a key building block, as well as how a new Business Unit for Electrolyzer & Fuel Cell Technologies will help bend the…

1
Enabling the Nervous System to Repair Itself 17:22

4M ago17:22

17:22

About 500,000 people suffer from a spinal cord injury each year. Treatments can involve surgical procedures to stabilize the spine and physical rehabilitation, which can have limited benefits. There are currently no FDA-approved therapies that can promote repair and improve function following a spinal cord injury. NervGen Pharma is seeking to chang…

1
Overcoming Barriers to Delivering Large Molecules to the Brain 18:14

4M ago18:14

18:14

One of the challenges of treating neurodegenerative diseases is delivering therapies across the blood-brain barrier. Aliada Therapeutics is developing therapies that use its platform technology that enables the delivery of large molecules, like antibodies, across that barrier. Its lead program is in development to treat Alzheimer’s disease. We spok…

들어볼 가치가 있는 팟캐스트

Media Molecule 팟 캐스트

들어볼 가치가 있는 팟캐스트

1
Media Molecule Podcast

Media Molecule

1
The Bio Report

Levine Media Group

1
Everything About Hydrogen

Hydrogen Media Ltd

1
ReLoaded Gaming Podcast

ReLoaded Gaming Podcast

1
Wisdom Podcast with Katerina Satori

Katerina Satori: Transdimentional Seer - Wisdom Channel - Mystical Mentor

1
Energy Policy with Your Favorite Professor starring Marco Dell’Aquila, Co-founder & Chairman of Power Capital and Inspiratia 1:03:04

1
Targeting Senescent Cells to Treat Aging-Related Diseases 31:44

1
Bringing Cellular Diversity into Sharper Focus 30:35

1
Developing Cancer Therapies for When Damage Control Goes Awry 18:09

1
Delivering the Goods 36:06

1
Driving the Green Transformation through Innovation & Cooperation with Miguel Ángel López Borrego, CEO of thyssenkrupp AG and thyssenkrupp Decarbon Technologies 54:37

1
Swimming in the New Oil 22:26

1
Does This Drug Represent “A Paradigm Shift for Small Molecule Drug Development?” 28:01

1
Exploring the Promise and Peril of CRISPR 57:36

1
Transforming Protein Engineering with Generative AI 35:47

1
Delivering Peptide Therapies Orally 34:06

1
Creating A Drug Delivery ARMMs Race 24:42

1
From Vision to Reality: Producing Sustainable Molecules with Gene Gebolys, World Energy Founder & CEO 55:12

1
A Seek and Destroy Approach to Disease-Causing Proteins 37:10

1
Teaching Tolerance to Address Autoimmune Diseases 36:25

1
Nuclear-enabled Hydrogen at Port of Belledune with Rishi Jain, MD of Cross River Infrastructure Partners 51:35

1
A Bet That the Next Blockbuster May Already Be Inside You 22:34

1
A Big Mac Attack to Fight Cancer 36:37

1
Getting Animated about Bioliteracy 24:29

1
Finding Your True Direction in Life 33:06

1
Optimizing the Capital Stack with Bart White, EMEA Head of Energy Structured Finance at Santander Corporate and Investment Banking 46:53

1
Reshaping Clinical Trial Designs with Real-World Data 28:53

1
Using Generative AI to Produce Precise Gene Editors 23:15

1
Alfa Laval Inside with Tue Johannessen, Alfa Laval VP Strategy & Partnerships, Electrolyzer & Fuel Cell Technologies 56:43

1
Enabling the Nervous System to Repair Itself 17:22

1
Overcoming Barriers to Delivering Large Molecules to the Brain 18:14

빠른 참조 가이드